| # | Drug | Count |
|---|---|---|
| 0 | RISANKIZUMAB-RZAA | 35 |
| 1 | UPADACITINIB | 31 |
| 2 | ADALIMUMAB | 25 |
| 3 | VEDOLIZUMAB | 16 |
| 4 | ORAL SEMAGLUTIDE | 15 |
| 5 | ADALIMUMAB-ADAZ | 11 |
| 6 | ERGOCALCIFEROL | 11 |
| 7 | INFLIXIMAB | 11 |
| 8 | TOFACITINIB | 11 |
| 9 | ADALIMUMAB-AATY | 10 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ESTRADIOL AND NORETHINDRONE ACETATE | 1 | 0.0026 |
| 1 | SIBEPRENLIMAB | 1 | 0.0015 |
| 2 | INFLIXIMAB-DYYB | 5 | 0.0015 |
| 3 | PEXIDARTINIB HYDROCHLORIDE | 1 | 0.0014 |
| 4 | COAL TAR | 1 | 0.0013 |
| 5 | PITOLISANT HYDROCHLORIDE | 2 | 0.0009 |
| 6 | CLEAR MINT, GEL TOOTHPASTE | 1 | 0.0009 |
| 7 | SODIUM FLUORIDE F18 | 1 | 0.0009 |
| 8 | SODIUM FLUORIDE F-18 | 1 | 0.0009 |
| 9 | RILONACEPT | 1 | 0.0009 |
| # | Drug class | Count |
|---|---|---|
| 0 | Interleukin-23 Antagonist [EPC] | 44 |
| 1 | Janus Kinase Inhibitor [EPC] | 32 |
| 2 | Tumor Necrosis Factor Blocker [EPC] | 28 |
| 3 | GLP-1 Receptor Agonist [EPC] | 20 |
| 4 | Corticosteroid [EPC] | 19 |
| 5 | Integrin Receptor Antagonist [EPC] | 16 |
| 6 | Nonsteroidal Anti-inflammatory Drug [EPC] | 15 |
| 7 | Atypical Antipsychotic [EPC] | 12 |
| 8 | Provitamin D2 Compound [EPC] | 11 |
| 9 | Folate Analog Metabolic Inhibitor [EPC] | 10 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 1 | 0.0015 |
| 1 | alpha-Hydroxy Acid [EPC] | 1 | 0.0005 |
| 2 | Thyroid Hormone Receptor beta Agonist [EPC] | 1 | 0.0004 |
| 3 | Calcitonin Gene-related Peptide Receptor Antagonist [EPC] | 3 | 0.0004 |
| 4 | Interleukin-23 Antagonist [EPC] | 44 | 0.0004 |
| 5 | Provitamin D2 Compound [EPC] | 11 | 0.0004 |
| 6 | Serotonin and Norepinephrine Reuptake Inhibitor [EPC] | 1 | 0.0003 |
| 7 | Dopamine and Norepinephrine Reuptake Inhibitor [EPC] | 1 | 0.0003 |
| 8 | Uric Acid-specific Enzyme [EPC] | 1 | 0.0003 |
| 9 | Antihypoglycemic Agent [EPC] | 1 | 0.0002 |